Medical Condition News

RSS

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

Gilead Sciences, Inc. today announced that its head-to-head Phase III clinical trial of Cayston (aztreonam for inhalation solution) versus tobramycin inhalation solution in cystic fibrosis patients with Pseudomonas aeruginosa achieved one of its co-primary endpoints of non-inferiority for mean percent change in forced expiratory volume in one second (FEV1) percent predicted after 28 days of treatment.

19 Jun 2010

esperanza Magazine's feature article Marriage Matters wins 2010 MHA Media Award

esperanza Magazine's feature article "Marriage Matters" has won a Mental Health America 2010 Media Award in the national magazine category. esperanza Magazine was among 15 media outlets honored by MHA at an awards luncheon held June 12 during the advocacy organization's 2010 annual conference in Washington, DC. The awards honor excellence in reporting and portrayals of mental health issues.

19 Jun 2010

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

Ancient circadian clock regulates insulin production

The pancreas has its own molecular clock. Now, for the first time, a Northwestern University study has shown this ancient circadian clock regulates the production of insulin. If the clock is faulty, the result is diabetes.

19 Jun 2010

Memory Ride to raise money and awareness to fight Alzheimer's disease

Hundreds of cyclists, from experienced to novice, are signing up for Memory Ride to raise money and awareness to fight Alzheimer's disease. Set for Saturday, July 24, Memory Ride offers a challenging 100-mile "century" ride, as well as a "metric century" of 62 miles and a 20-mile option.

19 Jun 2010

Tea and coffee consumption linked with reduced heart disease: Study

Coffee and tea drinkers may not need to worry about indulging - high and moderate consumption of tea and moderate coffee consumption are linked with reduced heart disease, according to a study published in Arteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association.

19 Jun 2010

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

The first data to show that Neupro® (rotigotine transdermal system) significantly improved wellbeing and daily activities that are often impaired by pain related to Restless Legs Syndrome (RLS) were presented this week at the 14th International Congress of Parkinson's Disease and Movement Disorders in Buenos Aires, Argentina.

18 Jun 2010

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

Ardea Biosciences, Inc. announced that additional positive data from its Phase 2 program for RDEA594, its lead product candidate for the treatment of hyperuricemia and gout, are being presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Rome, Italy. RDEA594, a first-in-class selective inhibitor of the URAT1 transporter, treats the underlying cause of gout by increasing the excretion of uric acid in order to bring the body's levels of uric acid into a normal range.

18 Jun 2010

St. Jude Medical's Therapy Cool Flex Ablation Catheter granted European CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of the Therapy™ Cool Flex™ Ablation Catheter at the 17th World Congress in Cardiac Electrophysiology and Cardiac Techniques (CardioStim). The ablation catheter is the industry's first to have a fully-irrigated and flexible tip, which can potentially improve the safety and efficacy of cardiac ablation procedures.

18 Jun 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.

18 Jun 2010

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

Inspire Pharmaceuticals, Inc. announced today that data is being presented on denufosol tetrasodium, an investigational therapy for cystic fibrosis (CF), during an oral presentation and poster presentations at the 33rd Annual European Cystic Fibrosis Society (ECFS) Conference June 16 - 19, 2010 in Valencia, Spain.

18 Jun 2010

SLE and RA negatively affect patients' emotional relationships, sex lives: Study

Systemic Lupus Erythematosus patients from Brazil and Rheumatoid Arthritis patients from France report that their rheumatic conditions negatively affect their emotional relationships and sex lives, according to research presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Women receive greater clinical benefit from CRT-Ds than men: Study

Boston Scientific Corporation today announced results from a sub-analysis of the MADIT-CRT trial data that showed women received a greater clinical benefit from its cardiac resynchronization therapy defibrillators (CRT-Ds) than men. The results were presented during the 17th Cardiostim World Congress by Jonathan Steinberg, M.D., Chief of Cardiology and Director of the Al-Sabah Arrythmia Institute, St. Luke's-Roosevelt Hospital Center, New York.

18 Jun 2010

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

Two separate studies have shown that vitamin D deficiency is common in patients with a range of rheumatic diseases, with over half of all patients having below the 'normal' healthy levels of vitamin D (48-145 nmol/L) in their bodies. A further study assessing response to vitamin D supplementation found that taking the recommended daily dose did not normalise vitamin D levels in rheumatic disease patients.

18 Jun 2010

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

InteKrin Therapeutics Inc. announced today it will present 6 month Phase 2b clinical data for edema in diabetic patients showing differentiation for INT131, a Selective PPAR-gamma Modulator (SPPARM), from Actos® pioglitazone, at the American Diabetes Association annual meeting in Orlando, FL, Monday, June 28, 2010 at 2:45 pm EDT during the "Update on BARI 2D --Treatment of Insulin Resistance" session.

18 Jun 2010

Risk of MI increases six-fold in young women with RA: Study

Rheumatoid Arthritis patients face a two-fold increased risk of suffering a Myocardial Infarction (MI, heart attack) versus the general population, which is comparable to the increased risk of MI seen in diabetes patients, according to results of a new study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

USFDA approves Sun Pharma's generic Xanax ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax®, alprazolam tablets.

18 Jun 2010

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced the presentation of additional results from BLISS-52, one of two pivotal Phase 3 trials of BENLYSTA (belimumab) in seropositive patients with systemic lupus erythematosus. The additional data will be presented in Rome at the 2010 Congress of the European League against Rheumatism on Saturday, June 19.

18 Jun 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

The expression of a transporter protein called the Breast Cancer Resistance Protein in rheumatoid arthritis patients may indicate higher disease activity and could be a barrier to the effectiveness of disease-modifying antirheumatic drugs, according to the results of a study presented today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy.

18 Jun 2010

Interim epidemiological information on SLE patients in China presented at EULAR 2010

The Chinese Systemic Lupus Erythematosus Treatment and Research Group (CSTAR) announced interim epidemiological information on SLE patients in China today at EULAR 2010, the Annual Congress of the European League Against Rheumatism in Rome, Italy. Robust data on SLE patients has been scarce to date; but now CSTAR provides the first online registry of this magnitude in China. To date the registry has collated data from 2,104 SLE patients across 30 Chinese provinces.

18 Jun 2010

Medical Condition News

Phase III clinical trial data of Cayston versus TIS in CF patients with P. aeruginosa presented at ECFC 2010

esperanza Magazine's feature article Marriage Matters wins 2010 MHA Media Award

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

Ancient circadian clock regulates insulin production

Memory Ride to raise money and awareness to fight Alzheimer's disease

Tea and coffee consumption linked with reduced heart disease: Study

Neupro improves wellbeing impaired by pain related to Restless Legs Syndrome

Additional positive data from Ardea Biosciences' RDEA594 Phase 2 program presented at EULAR

St. Jude Medical's Therapy Cool Flex Ablation Catheter granted European CE Mark approval

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Inspire's TIGER-1 Phase 3 clinical trial data with denufosol for CF presented at 33rd ECFS

SLE and RA negatively affect patients' emotional relationships, sex lives: Study

Women receive greater clinical benefit from CRT-Ds than men: Study

Recommended supplementation not sufficient to normalise vitamin D levels in RA patients: Study

InteKrin Therapeutics to present INT131 SPPARM Phase 2b data at American Diabetes Association meeting

Risk of MI increases six-fold in young women with RA: Study

USFDA approves Sun Pharma's generic Xanax ANDA

Additional results from BLISS-52 Phase 3 trial of BENLYSTA for SLE to be presented at EULAR 2010

Expression of BCRP in RA patients may indicate higher disease activity, predict resistance to DMARDs

Interim epidemiological information on SLE patients in China presented at EULAR 2010

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Precision in every drop: Inside Hamilton’s syringe technology

Latest News